Effect of resveratrol in type 2 diabetes oxidative stress markers: a reassessment

Venu Gopal Jonnalagadda¹ · Harish Prabhanna Char²

Received: 24 January 2018 / Accepted: 2 May 2018 / Published online: 23 May 2018
© Springer-Verlag Italia S.r.l., part of Springer Nature 2018

Dear Editor,

We have read the research article “The effects of resveratrol on markers of oxidative stress in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial” by Seyyedebrahimi et al., the authors presented comparative study results of resveratrol on oxidative stress parameters in type 2 diabetes mellitus (T2DM) participants [1]. We would like to request the authors to clarify or elucidate the following points for further understanding.

First, the authors mentioned that participants were randomized using a stratification method in a double-blind manner and did not mention about the criteria for the same [1]. However, stratification method can be performed based on different factors, i.e., gender, age or other demographic characteristics and leads to bias in grouping [2].

Second, the authors mentioned that patients were refrained from the anti-inflammatory supplementation during the entire study. However, the patients were on statins in

both the groups, i.e., 75% in placebo and 70% in resveratrol and these itself have an anti-inflammatory effect [3].

Third, in Fig. 1, the number of participants in the placebo group was presented as 25, but, in Table 1 it is mentioned as 18.

Fourth, a dose of resveratrol was considered as 800 mg/day, but, did not mention the reference for this dose as 800 mg/day seems to be high.

Fifth, the baseline HOMA-IR value of placebo mentioned as 5.75 ± 5.74 , which means the mean and the standard deviation in this group are same, i.e., 11.49 or 0.01. Thus, there is a large variation in this group.

We would be highly obliged for your kind consideration of the above-mentioned clarifications in your article to understand more beneficial effects of bioactive compound i.e., resveratrol on oxidative parameters in T2DM.

Funding This paper was not funded.

Compliance with ethical standards

Conflict of interest The authors declare that they have no competing interests. The authors have no relevant affiliations or financial involvement with any organization or entity.

References

1. Seyyedebrahimi S, Khodabandehloo H, Nasli Esfahani E, Meshkani R (2018) The effects of resveratrol on markers of oxidative stress in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. *Acta Diabetol*. <https://doi.org/10.1007/s00592-017-1098-3>
2. Polit DF, Beck CT (2008) Nursing research: generating and assessing evidence for nursing practice, 9th edn. Wolters Kluwer Health, Lippincott Williams & Wilkins, Philadelphia
3. Lefer DJ (2002) Statins as potent antiinflammatory drugs. *Circulation* 106:2041–2042

Managed by Massimo Porta.

This comment refers to the article available at <https://doi.org/10.1007/s00592-017-1098-3>.

Reply to this comment refers to the article available at <https://doi.org/10.1007/s00592-018-1154-7>.

✉ Venu Gopal Jonnalagadda
gopalvenu63@gmail.com

Harish Prabhanna Char
pharish9@gmail.com

¹ Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, C/O NETES Institute of Technology and Science, NH-37, Shantipur, Parli Part, Mirza, Assam 781125, India

² National Institute of Management Studies, 201 Nirman Estate, Link Road, Malad West, Mumbai, Maharashtra 400064, India